Literature DB >> 18790190

Heat inactivation can differentiate between IgG and IgM antibodies in the pretransplant cross match.

I A Al-Muzairai1, M Mansour, L Almajed, N Alkanderi, N Alshatti, M Samhan.   

Abstract

The presence of IgG antibodies in the pretransplant cross-match (XM) test results in hyperacute rejection, but IgM antibodies are inconsequential. The XM should be able to differentiate between IgG and IgM antibodies. This study evaluated 3 methods. This study was based on 500 patients for whom XM were performed between 2004 and 2006 with all 3 techniques. Two patient sera were used: normal serum and heat inactivated serum, which was prepared by incubating patient serum at 63 degrees C for 10 minutes to destroy IgM antibodies. The efficiencies of flow cytometry XM (FC-XM), dithiothreitol complement-dependent microlymphocytotoxicity (DTT/CDC-XM), and heat inactivation (HI-CDC-XM) to differentiate between IgG and IgM were evaluated by using both sera. Patients with positive XM, and negative HI-CDC-XM were reported as negative XM. During the study period, there were 70 patients with positive B-cell XM. Forty-nine became negative after HI-XM, and 21 remained positive. Only 34 cases became negative after DTT-CDC-XM and 36 remained positive. HI-CDC-XM was comparable to FC-XM; all patients testing negative with this technique experienced successful renal transplantations without hyperacute, accelerated, or acute rejection episodes. Our study showed that HI-CDC-XM was effective at exclude donor-specific IgM antibodies, a result which was comparable to FCXM to detect only IgG antibodies. HI is simple and rapid and does not involve any extra equipment or cost.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18790190     DOI: 10.1016/j.transproceed.2008.07.045

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  7 in total

1.  False negative single antigen bead assay: Is it always an effect of prozone?

Authors:  Dharmendra Jain; Jui Choudhuri; Rajni Chauhan; Pranav Dorwal; Deepak Sharma; Aseem K Tiwari; Vimarsh Raina
Journal:  J Clin Lab Anal       Date:  2017-04-26       Impact factor: 2.352

2.  Endotoxin neutralization as a biomonitor for inflammatory bowel disease.

Authors:  Keith Champion; Laura Chiu; John Ferbas; Michael Pepe
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

3.  Persistence of the protective immunity and kinetics of the isotype specific antibody response against the viral nucleocapsid protein after experimental Schmallenberg virus infection of sheep.

Authors:  Antoine Poskin; Stephanie Verite; Loic Comtet; Yves Van der Stede; Brigitte Cay; Nick De Regge
Journal:  Vet Res       Date:  2015-10-15       Impact factor: 3.683

4.  Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019.

Authors:  Peter D Burbelo; Francis X Riedo; Chihiro Morishima; Stephen Rawlings; Davey Smith; Sanchita Das; Jeffrey R Strich; Daniel S Chertow; Richard T Davey; Jeffrey I Cohen
Journal:  J Infect Dis       Date:  2020-06-29       Impact factor: 5.226

5.  Evaluation of Erythrocytes Magnetized Technology for Measurement of ABO Isoagglutinin Titers.

Authors:  Parul Chopra; Sunanda Bhardwaj; Ajay Samkaria; Asha Amoli; Anil Arora
Journal:  J Lab Physicians       Date:  2021-07-15

6.  Comparison of antibody titers using conventional tube technique versus column agglutination technique in ABO blood group incompatible renal transplant.

Authors:  Amit Bhangale; Amardeep Pathak; Smita Pawar; Tarun Jeloka
Journal:  Asian J Transfus Sci       Date:  2017 Jul-Dec

7.  Detection of Nucleocapsid Antibody to SARS-CoV-2 is More Sensitive than Antibody to Spike Protein in COVID-19 Patients.

Authors:  Peter D Burbelo; Francis X Riedo; Chihiro Morishima; Stephen Rawlings; Davey Smith; Sanchita Das; Jeffrey R Strich; Daniel S Chertow; Richard T Davey; Jeffrey I Cohen
Journal:  medRxiv       Date:  2020-04-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.